From Seekingalpha · · 40s
MiniMed's Product Cycle Hides Split-Off Hangover
MiniMed's split-off obscures product-cycle progress despite strong Q1 growth.
In brief
MiniMed's split-off obscures product-cycle progress despite strong Q1 growth. MiniMed Group's Q1 organic growth accelerated to 15.8% with new U.S. pump volumes rising over 20% as it shifts from share donor to share taker. Originally reported by Seekingalpha.
MiniMed Group

MiniMed Group's Q1 organic growth accelerated to 15.8% with new U.S. pump volumes rising over 20%.
Product Cycle Progress
Flex, the Fit patch pump, and Vivera could complete MiniMed's portfolio by late 2027 despite regulatory, competitive, and separation risks.
Share Taker Shift
MiniMed is priced at 1.43x forward EV/sales with potential recovery from easing split-off supply and improved cash conversion.
The big picture
MiniMed Group's Q1 organic growth accelerated to 15.8% with new U.S. pump volumes rising over 20% as it shifts from share donor to share taker.
Read the TL;DR — this story on one card.
